Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734512 · ClinicalTrials.gov registry record · Phase 2
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01734512 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 65 participants.
The verdict
NCT01734512, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-12-13 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01734512
The ClinicalTrials.gov registry entry for NCT01734512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT01734512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01734512 about?
NCT01734512 is a clinical study titled "PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children". This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
What is the current status of trial NCT01734512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-12-13. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT01734512?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT01734512?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.